Analyst Price Target is $33.00
▲ +381.75% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Enlivex Therapeutics in the last 3 months. The average price target is $33.00, with a high forecast of $33.00 and a low forecast of $33.00. The average price target represents a 381.75% upside from the last price of $6.85.
Current Consensus is
The current consensus among 1 polled investment analysts is to buy stock in Enlivex Therapeutics.
Enlivex Therapeutics Ltd. develops autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions. It produces treatment devices for CAR-T cancer treatment procedures, Graft-versus-Host disease resulting from bone-marrow transplantations, solid organ transplantations and an assembly of autoimmune and inflammatory conditions, such as Crohn's disease, rheumatoid arthritis, gout, multiple sclerosis and other disorders. The company was founded on January 22, 2012 and is headquartered in Nes-Ziona, Israel.